title: Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
abstract: OBJECTIVE
  To review clinical evidence for the efficacy, safety, and tolerability of dapagliflozin (Farxiga-AstraZeneca), a sodium glucose cotransporter 2 inhibitor, as monotherapy or in combination with other hypoglycemic agents for the treatment of type 2 diabetes.
  
  
  METHODS
  Literature was identified through a systematic MEDLINE search of clinical trial results for dapagliflozin.
  
  
  RESULTS
  Multiple controlled clinical trials have established the efficacy, safety, and tolerability of dapagliflozin as monotherapy or in combination with other therapies for type 2 diabetes. Dapagliflozin is approved by Food and Drug Administration as monotherapy or as an add-on to other glucose lowering agents including insulin for the treatment of type 2 diabetes.
  
  
  CONCLUSIONS
  Dapagliflozin is effective for the treatment of type 2 diabetes.
authors.affiliation: Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, USA davisp@tsu.edu.
authors.forename: Portia N
authors.initials: PN
authors.lastname: Davis
authors.affiliation: Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, USA.
authors.forename: Uche Anadu
authors.initials: UA
authors.lastname: Ndefo
authors.affiliation: Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, USA.
authors.forename: Ashley
authors.initials: A
authors.lastname: Oliver
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin
keywords: ambulatory care; dapagliflozin; endocrinology; internal medicine; sodium glucose co-transporter inhibitor; type 2 diabetes